Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Drug-resistant mycobacterial infections are a serious global health challenge, leading to
high mortality and socioeconomic burdens in developing countries worldwide. New …

The COVID-19 pandemic is the third outbreak this century of a zoonotic disease caused by a
coronavirus, following the emergence of severe acute respiratory syndrome (SARS) in 2003 …

Background The ongoing COVID-19 pandemic has caused more than 193,825 deaths
during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic …

Candida glabrata is a major fungal pathogen notable for causing recalcitrant infections,
rapid emergence of drug-resistant strains, and its ability to survive and proliferate within …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Tuberculosis is a highly contagious disease spread by Mycobacterium tuberculosis. It is
responsible for highest numbers of death and soon will surpass the deaths caused by HIV …